Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2010
05/26/2010EP2187957A2 Selective cytopheresis devices and related methods thereof
05/26/2010EP2187956A2 Use of a laminin peptide as a therapeutic agent
05/26/2010EP2187952A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents
05/26/2010EP2187950A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
05/26/2010EP2187949A2 Use of glp-1 as a therapeutic agent
05/26/2010EP2187948A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187947A2 Use of calcitonin as anti-angiogenic agent
05/26/2010EP2187946A1 Use of a peptide as a therapeutic agent
05/26/2010EP2187945A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187944A1 Use of urodilatin as a therapeutic agent
05/26/2010EP2187942A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187940A1 Use of urocortin and corticotropin-releasing fact r as therapeutic agents
05/26/2010EP2187936A1 Minigastrin as a therapeutic agent
05/26/2010EP2187935A2 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
05/26/2010EP2187934A1 Use of fertirelin and delta-endorphin as therapeutic agents
05/26/2010EP2187933A1 Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
05/26/2010EP2187932A1 Protein formulations comprising gdf-5 in aqueous acidic solution
05/26/2010EP2187931A2 Use of a combination of cart peptides as a therapeutic agent
05/26/2010EP2187930A2 Trap-14 as a therapeutic agent
05/26/2010EP2187929A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187927A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
05/26/2010EP2187926A1 Prevention of type 1 diabetes by administration of gliadin
05/26/2010EP2187925A1 Use of human neuropeptide as a therapeutic agent
05/26/2010EP2187924A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187923A2 Use of acetyl-(ala10,11)-rantes(1-14) and/or calcitonin as anti-angiogenic agents
05/26/2010EP2187922A2 Use of a deslorelin and mastoparan as a therapeutic agent
05/26/2010EP2187921A2 Use of gonadorelin as a therapeutic agent
05/26/2010EP2187917A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent
05/26/2010EP2187915A2 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
05/26/2010EP2187914A2 Astressin and beta-endorphin for use as therapeutic agents
05/26/2010EP2187913A2 Use of the peptide rfmwmr as a therapeutic agent
05/26/2010EP2187912A2 Use of a peptide as a therapeutic agent
05/26/2010EP2187911A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
05/26/2010EP2187909A1 Use of bpp-b as a therapeutic agent
05/26/2010EP2187908A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent
05/26/2010EP2187907A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
05/26/2010EP2187906A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
05/26/2010EP2187905A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
05/26/2010EP2187902A2 Screening methods using g-protein coupled receptors and related compositions
05/26/2010EP2187901A2 Therapeutic use of neuropeptide ei and a acth 7-38 and compositions thereof
05/26/2010EP2187900A2 Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
05/26/2010EP2187898A1 Use of the cyp46a1 gene for the treatment of alzheimer's disease
05/26/2010EP2187890A1 Method for reducing intracranial pressure
05/26/2010EP2084183B1 Pegylated pth as pth receptor modulators and uses thereof
05/26/2010EP1947175B1 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
05/26/2010EP1781782B1 Modified vitamin k dependent polypeptides
05/26/2010EP1575379B1 Nutritional compositions
05/26/2010EP1572168B1 Anti-infarction molecules
05/26/2010EP1448602B1 Modified anti-tnf alpha antibody
05/26/2010EP1424998B1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
05/26/2010EP1370275B1 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
05/26/2010EP1307225B1 Antagonists of cd30 or cd30l for use in treating auto-immune and chronic inflammatory conditions
05/26/2010EP1272665B1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
05/26/2010EP1144642B1 Compounds and methods for treatment and diagnosis of chlamydial infection
05/26/2010EP1082875B1 Improved brush block housing for propeller deicing system
05/26/2010CN1974598B Isolated proteins from a traditional Chinese medicine yuzhu and use thereof
05/26/2010CN1912111B Engomphosis and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
05/26/2010CN1886150B Fibroblast-mobilizing agent containing G-CSF and wound remedy
05/26/2010CN1880457B Ad6 recombinant nucleic acid
05/26/2010CN1829735B Imaging agents
05/26/2010CN1803189B Use of neurotoxin therapy for treatment of urologic and related disorders
05/26/2010CN1798763B Phl p 5a derivatives with reduced allergenicity and retained T-cell reactivity
05/26/2010CN1771912B Orally taken nanometer protein polypetide composite nano-particle and its preparation
05/26/2010CN1753683B Ophthalmic formulation for the prevention and treatment of ocular conditions
05/26/2010CN1750809B Fast dissolving orally consumable films containing pharmaceutically active agents
05/26/2010CN1744913B Use of the cathelicidin LL-37 and derivatives thereof for wound healing
05/26/2010CN1733296B Stable liquid interferon formulations
05/26/2010CN1723219B Protein complex using immunoglobulin fragment and method for the preparation thereof
05/26/2010CN1711279B Epstein Barr virus peptide epitopes, polyepitopes and delivery system therefor
05/26/2010CN1671407B Compositions and methods for treating diabetes
05/26/2010CN1668637B Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
05/26/2010CN1665934B GNTIII(UDP-N-acetylglucosamine:beta-D mannoside beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants
05/26/2010CN1665933B Immunoconjugates for the treatment of tumours
05/26/2010CN1638807B Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
05/26/2010CN1604795B Combination motif immune stimulatory oligonucleotides with improved activity
05/26/2010CN1578833B Materials and methods for reducing oxalate concentrations in fluids
05/26/2010CN1518458B Graft rejection inhibitors
05/26/2010CN1468308B Anti-TNF antibodies, compositions, methods and uses
05/26/2010CN1425066B Novel stra6 polypeptides
05/26/2010CN1406245B Method of eliminating human serum albumin polymers
05/26/2010CN1359390B Factor VII a inhibitors
05/26/2010CN101715340A suspension formulations of insulinotropic peptides and uses thereof
05/26/2010CN101712964A Fusion protein for inhibiting formation of osteoclast and preparation method as well as pharmaceutical composition thereof
05/26/2010CN101712960A Mac-2BP tumor antigen gene, protein, antibody and application thereof
05/26/2010CN101712959A Novel human cell growth inhibiting gene THAP11 and application thereof
05/26/2010CN101712958A Novel human tumor inhibiting gene KIAA0157 and application thereof
05/26/2010CN101712722A Glp-1 fusion proteins
05/26/2010CN101712721A T cell receptor fusions and conjugates and methods of use thereof
05/26/2010CN101712720A Human antibodies that bind human TNF alpha
05/26/2010CN101712717A Novel small-molecule polypeptide blocking hepatitis B virus infection
05/26/2010CN101712688A Hybrid QA molecules wherein Q is an aminoquinoline and A is an antibiotic residue, their synthesis and their uses as antibacterial agent
05/26/2010CN101711877A Chitosan vehicle and method for making same
05/26/2010CN101711876A Polyethylene glycol modified recombinant human granulocyte colony-stimulating factor and preparation method thereof
05/26/2010CN101711874A Application of cell penetrating peptide Tat-mediated growth factor in transdermal transfer
05/26/2010CN101711868A Gene detection assay for improving the likelihood of an effective response to a ErbB antibody cancer therapy
05/26/2010CN101711862A Medicine target spot relevant to inflammatory diseases and application thereof
05/26/2010CN101711861A bacterial virulence factors and uses thereof
05/26/2010CN101711860A Application of laver phycobilin protein in preparing medicine used for resisting oxidation and enhancing immunity
05/26/2010CN101711859A Application of Hfq protein of staphylococcus aureus in preventing and treating staphylococcus aureus infection
05/26/2010CN101711858A Medicine for treating cancer
1 ... 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 ... 3163